Thanks Julie. In the second quarter, the Research Opportunities Fund Class I appreciated 5.06% compared to 5.06% compared to 2.69% for the Russell 3000. For the year-to-date period, the fund is up 18.68% compared to 14.06% for the Russell 3000 Benchmark. Since inception, the Research Opportunities fund has produced strong absolute returns, while trailing our long-only benchmark by a modest amount. This relative underperformance is not surprising in a sharply rising market environment. But over full market cycle, as we continue to expect positive relative returns, in addition to adequate, absolute returns. Turning to page 51, the fund has 69 long and 23 short positions at the end of the quarter, compared to 62 long and 20 short positions at the end of the first quarter. Gross exposure increased to 90.5% from 84% at the end of the first quarter, and our next exposure increased slightly to 68% from 66.5% at the end of the first quarter. Turnover at 40% is slightly higher than we would expect over the long term, as many of our positions increased to approach our estimates of intrinsic value. There are no significant changes during the quarter, based on a sector basis. Turning to page 53, looking at our top 10 holdings. New to our top 10 holdings in the quarter were AIG and Willis Group. These names replaced the Hartford, which was eliminated completely from the portfolio, and also Energizer. AIG was added during the first quarter, and the position size was increased during the second quarter, moving it into the top 10. Willis, one of the largest insurance brokers in the world is a new position during the quarter, and was added to replace the Hartford Group, which as I mentioned was eliminated. Looking at our new positions during the quarter, we had eight new long positions, and six eliminated positions. Of note during the quarter, three of our new long positions were international names. We had two ADRs based in Britain, the pharmaceutical company GlaxoSmithKline, and the retailer, Tesco, that were added; and Canadian pharmaceutical company Valeant, which is listed on the New York Stock Exchange, was also added during the quarter. Currently we have approximately 3.5% of the Research Opportunities fund in international holdings. Looking at the eliminated positions during the quarter; all the names with the exception of Devon, were at or nearing our estimates of intrinsic value. In the case of Devon, Devon was sold -- increased our position in Cimarex, where our analyst Suken Patel thought there was a better risk reward. Finally, turning to page 53 and looking at our best and worst performers; there were no significant contributors or detractors that have not -- already been addressed on this call. So at this point, I am going to go ahead and turn it back to Julie.